Document Detail


Chromium can reduce the mutagenic effects of benzo[a]pyrene diolepoxide in normal human fibroblasts via an oxidative stress mechanism.
MedLine Citation:
PMID:  9729358     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The interaction of multiple carcinogens on human cells has not been extensively examined. This study reports the results of experiments in which normal human fibroblasts were exposed to both benzo[a]pyrene diolepoxide (BPDE) and potassium dichromate. The effect of four different treatment protocols on the cloning ability of the cells and the mutant frequency of the HPRT gene was determined. The combined treatment of both carcinogens caused a slightly greater than additive decrease in the cloning ability of the cells when compared to cells treated with the individual carcinogens. The result was the same regardless of the treatment protocol used in the experiment. The results of the mutant frequency experiments, however, varied dramatically with the protocol employed. The mutant frequency in cells which were simultaneously treated with both carcinogens was dramatically reduced from the mutant frequency found when cells were treated with BPDE alone. This antagonistic effect was not present when cells were either pretreated with potassium dichromate prior to BPDE or incubated with potassium dichromate following BPDE treatment. The observed antagonistic effect was the result of oxidative stress produced by chromium since it was completely or nearly completely reversed by the addition of either vitamin E or catalase to the cultures.
Authors:
Y Tesfai; D Davis; D Reinhold
Related Documents :
3780748 - Asn-linked oligosaccharides in lectin-resistant tumor-cell mutants with varying metasta...
7651468 - Streptozotocin-induced genotoxic effects in chinese hamster cells: the resistant phenot...
2827018 - The induction of chromosome aberrations by restriction endonucleases that produce blunt...
10656388 - In vitro efficacy of a novel chemoradiopotentiator--taxoltere metro.
17308608 - Precise multipass herriott cell design: derivation of controlling design equations.
8188248 - Human r1 subunit of ribonucleotide reductase (rrm1): 5' flanking region of the gene.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Mutation research     Volume:  416     ISSN:  0027-5107     ISO Abbreviation:  Mutat. Res.     Publication Date:  1998 Aug 
Date Detail:
Created Date:  1998-09-28     Completed Date:  1998-09-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0400763     Medline TA:  Mutat Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  159-68     Citation Subset:  IM    
Copyright Information:
Copyright 1998 Elsevier Science B.V.
Affiliation:
Departments of Chemistry and Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide / toxicity*
Antimutagenic Agents / pharmacology*
Cells, Cultured
Chromium / pharmacology*
Colony-Forming Units Assay
Drug Interactions
Fibroblasts
Humans
Hypoxanthine Phosphoribosyltransferase / genetics
Mutagenicity Tests
Mutagens / toxicity*
Oxidative Stress
Reactive Oxygen Species / metabolism
Chemical
Reg. No./Substance:
0/Antimutagenic Agents; 0/Mutagens; 0/Reactive Oxygen Species; 55097-80-8/7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; 7440-47-3/Chromium; EC 2.4.2.8/Hypoxanthine Phosphoribosyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neurop...
Next Document:  Immobility and flight associated with antinociception produced by activation of the ventral and late...